Objective: The aim of this study is to identify the prognostic significance of X-ray cross-complementing gene 1(XRCC1) in patients with gastric cancer undergoing surgery and platinum-based adjuvant chemotherapy.Methods: Immunohistochemistry(IHC) was used to evaluate XRCC1 protein expression profiles on surgical specimens of 612 gastric cancer patients. The relationship between XRCC1 expression and existing prognostic factors, platinum-based adjuvant chemotherapy, disease-free survival(DFS) and overall survival(OS) were analyzed.Results: Among 612 patients staged II/III in our study, 182(29.74%) were evaluated as XRCC1 IHC positive. XRCC1 expression was not significantly related to OS(P=0.347) or DFS(P=0.297). Compared with surgery only, platinum-based adjuvant chemotherapy significantly improved the OS(P=0.031). And the patients with negative XRCC1 expression benefited more from platinum-based adjuvant chemotherapy(P=0.049). Multivariate analysis demonstrated that tumor size, T category, N category, vascular or nerve invasion and platinum-based chemotherapy were good prognostic factors for OS(P<0.05). Though XRCC1 plays an important role in DNA repair pathways, no significant relationship is found in XRCC1 expression and OS among gastric cancer in our study.Conclusions: XRCC1 might be an alternative prognostic marker for the patients of gastric cancer after radical resection. The patients with negative XRCC1 expression can benefit more from platinum-based adjuvant chemotherapy. Objective: The aim of this study is to identify the prognostic significance of X-ray cross-complementing gene 1 (XRCC1) in patients with gastric cancer undergoing surgery and platinum-based adjuvant chemotherapy. Methods: Immunohistochemistry (IHC) was used to evaluate XRCC1 Protein expression profiles on surgical specimens of 612 gastric cancer patients. The relationship between XRCC1 expression and existing prognostic factors, platinum-based adjuvant chemotherapy, disease-free survival (DFS) and overall survival (OS) were analyzed. Results: Among 612 patients staged Compared with OS (P = 0.347) or DFS (P = 0.297). Compared with surgery only, platinum-based adjuvant chemotherapy significantly improved the OS (P = 0.031). And the patients with negative XRCC1 expression benefited more from platinum-based adjuvant chemotherapy (P = 0.049). Multivariate analysis test that tumor size, T categorization X, N category, vascular or nerve invasion and platinum-based chemotherapy were good prognostic factors for OS (P <0.05). Although XRCC1 plays an important role in DNA repair pathways, no significant relationship is found in XRCC1 expression and OS among gastric cancer in our study. Confc: XRCC1 might be an alternative prognostic marker for the patients of gastric cancer after radical resection. The patients with negative XRCC1 expression can benefit more from platinum-based adjuvant chemotherapy.